檢索結果 - Prianka Singh
- Showing 1 - 3 results of 3
-
1
-
2
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer 由 Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Méndez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre, Hope E. Uronis, Elena Elimova, Cecile Grootscholten, Karen Geboes, S. Yousuf Zafar, Stephanie Snow, Andrew H. Ko, Kynan Feeney, Michael Schenker, Piotr Kocoń, Jenny Zhang, Li Zhu, Ming Lei, Prianka Singh, Kaoru Kondo, James M. Cleary, Markus Moehler
出版 2021Artigo -
3
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial 由 Thomas Yau, Peter R. Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Jean‐Frédéric Blanc, Joong‐Won Park, Edward Gane, Matthias Pinter, Ana Matilla Peña, Masafumi Ikeda, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Hong Jae Chon, Joanna Wójcik-Tomaszewska, Gontran Verset, Qi Qi Wang, Caitlyn Stromko, Jaclyn Neely, Prianka Singh, Maria Jesus Jimenez Exposito, Masatoshi Kudo
出版 2025Artigo
相關主題
Medicine
Cancer
Immunotherapy
Internal medicine
Nivolumab
Oncology
Adenocarcinoma
Adjuvant
Chemoradiotherapy
Clinical trial
Esophageal cancer
Esophagectomy
Gastroenterology
Gastroesophageal Junction
Head and neck
Hepatocellular carcinoma
Ipilimumab
Lenvatinib
Medical physics
Open label
Sorafenib
Surgery